Scholars Central

Mini reviewPublished 4 Dec 2019

Imeglimin: Therapeutic Option for Achieving Glycemic Control

Authors: Dr. Subhash Kumar

Journal of Diabetes & Metabolism

Volume 10 · Issue 11 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Imeglimin is a new class of drug which has introduced recently. The molecular mechanisms are unknown, although imeglimin improves insulin sensitivity in humans. Pre-clinical studies had confirmed that imeglimin favouring lipid oxidation in liver and preserving mitochondrial function from oxidative stress, therefore normalizes glucose tolerance and insulin sensitivity. The main objective of this review article is to highlight updates of new class of drug which is imeglimin and generated a huge interest after recently conducted EASD at Barcelona.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Diabetes & Metabolism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Diabetes & Metabolism
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Dr. Subhash Kumar”